Building B
11 HaMenofim Street
Herzliya 4672562
Israel
972 9 799 6183
https://www.neurosense-tx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 18
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Or Eisenberg | Chief Financial Officer | 382k | N/A | 1981 |
Dr. Ferenc Tracik M.D. | Chief Medical Officer | 532k | N/A | 1964 |
Mr. Alon Ben-Noon | Co-Founder, CEO & Director | 619k | N/A | 1979 |
Ms. Hagit Binder | Chief Operation Officer | N/A | N/A | 1978 |
Dr. Niva Russek-Blum Ph.D. | Chief Technology Officer | N/A | N/A | 1979 |
Ms. Yael Barak | VP of Quality & Compliance | N/A | N/A | 1970 |
Ms. Keren Pushett | Head of HR | N/A | N/A | N/A |
Mr. Eidan Loushi | C.R.A. | N/A | N/A | N/A |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.